Law360, New York (September 27, 2005, 12:00 AM ET) -- Biovail Laboratories International SRL has brought a lawsuit against Watson Laboratories Inc. in order to prevent the drug maker from marketing a generic form of the anti-depressant Wellbutrin XL.
Watson informed Biovail in a letter dated July 21, 2005 that it had filed an Abbreviated New Drug Application with the Food and Drug Administration in hopes of producing a generic version of Wellbutrin XL.
Biovail asked Watson to provide information about the drug that would allow the company to determine whether or not its patent had...
Biovail Seeks To Block Generic Competiton For Wellbutrin XL
To view the full article, take a free trial now.
